Finerenone

A non-steroidal mineralocorticoid receptor antagonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥987.00

790.00

- +
10mg

￥1525.00

1220.00

- +
25mg

￥3050.00

2440.00

- +
50mg

￥4850.00

3880.00

- +
100mg

￥7775.00

6220.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx30654
CAS: 1050477-31-0
别名: 非奈利酮,BAY 94-8862
分子式: C21H22N4O3
分子量: 378.42
纯度: >98%
溶解度: DMSO : 100 mg/mL?(DMSO moisture absorption will reduce the solubility of the compound, please use a new DMSO; Need ultrasonic)
储存: Store at -20°C
库存: 现货

Background

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (IC₅₀ = 18 nM).¹ It is selective for the mineralocorticoid receptor over glucocorticoid, progesterone, and androgen receptors (IC₅₀s = >10,000 nM for all), as well as L-type calcium channels (IC₅₀ = >10,000 nM). Finerenone (3 mg/kg) reduces renal vasculopathy, fibrosis, and tubular degeneration, as well as cardiac fibrosis, in a rat model of hypertension-induced end-organ damage.² It also increases exercise capacity and prevents diastolic dysfunction in ovariectomized mice.³

1.Kolkhof, P., Jaisser, F., Kim, S.-Y., et al.Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedsideHandb. Exp. Pharmacol.243271-305(2017) 2.Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damageAm. J. Nephrol.52(8)642-652(2021) 3.Pieronne-Deperrois, M., Guéret, A., Djerada, Z., et al.Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized miceESC Heart Fail.8(3)1933-1943(2021)